A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung (The GRAIL Study)
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Ganciclovir (Primary) ; Valganciclovir
- Indications Cytomegalic inclusion disorders
- Focus Therapeutic Use
- Acronyms GRAIL
- 21 Aug 2018 Biomarkers information updated
- 23 Sep 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 according to ClinicalTrials.gov record.
- 23 Sep 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Aug 2015 according to ClinicalTrials.gov record.